<?xml version="1.0" encoding="UTF-8"?>
<p>At present, there are more than 200 ongoing clinical studies enlisted regarding the use of CQ/HCQ alone or in combination with macrolides (azithromycin or clarithromycin) as treatment or as pre- or post-exposure prophylaxis in COVID-19 patients. Although positive results were obtained in small size clinical studies, the recent data collected from larger size studies indicate that these drugs have no significant benefit in clinical outcome; moreover, their association with macrolides might augment the risk of cardiac adverse effects (arrhythmia) and mortality of hospitalized patients [
 <xref rid="B98-jcm-09-02084" ref-type="bibr">98</xref>].
</p>
